BRIDGE BIOTHERAPEUTICS INC.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Bridge Biotherapeutics Announces FDA Orphan Drug Designation for BBT-877 in Idiopathic Pulmonary Fibrosis (IPF) 2019-01-16 22:00
Bridge Biotherapeutics Announces a Successful Activation of U.S. Clinical Trial Sites for BBT-401 Phase 2 Study 2018-12-28 07:00
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate 2018-12-19 08:00
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-877, an Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis 2018-11-19 07:00
The First Pellino-1 Inhibitor BBT-401 Confirms Its Safety and Tolerability from the Phase I Study 2018-11-12 16:00
Bridge Biotherapeutics Presented Preclinical Study Results on BBT-877, an Autotaxin inhibitor at the IPF Summit 2018 2018-08-23 06:00
1 2 3